STOK Stoke Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1623526 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-86.3%
TTM net income YoY-699.5%
TTM EPS YoY-655.9%
Revenue 3-yr CAGR45.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-913.1%
Net margin-862.1%
FCF margin-764.7%
EBITDA margin-906.9%
Returns
ROE-73.6%
ROA-63.4%
ROIC (approx.)-86.6%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets13.3%
Debt / equity0.00x
Current ratio7.24x
Interest coverage-4,088.90x
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-8.6%
Payout ratio—
Capex / revenue19.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $11.26M | $9.32M | $6.23M | $1.40M | $10.63M | $13.82M | $158.57M | $22.61M |
| R&D expense | $59.83M | $49.50M | $39.67M | $41.70M | $37.70M | $25.86M | $32.68M | $23.42M |
| SG&A expense | $28.74M | $25.25M | $19.97M | $21.15M | $16.03M | $15.26M | $14.65M | $12.84M |
| Operating income | -$77.31M | -$65.43M | -$53.42M | -$61.44M | -$43.09M | -$27.30M | $111.24M | -$13.65M |
| Interest expense | $20,000 | $17,000 | $23,000 | $3,000 | $3,000 | $3,000 | $1,000 | -$1,000 |
| Pretax income | -$73.64M | -$61.62M | -$50.00M | — | -$39.62M | -$23.48M | $114.16M | — |
| Income tax | $0 | $0 | $0 | $0 | -$1.28M | $0 | $1.28M | — |
| Net income | -$73.64M | -$61.62M | -$50.00M | -$57.93M | -$38.35M | -$23.48M | $112.88M | -$10.48M |
| EBITDA | -$76.86M | -$64.97M | -$52.98M | -$61.03M | -$42.65M | -$26.85M | $111.72M | -$13.13M |
| EPS (basic) | -1.08 | -0.93 | -0.79 | — | -0.65 | -0.40 | 1.95 | — |
| EPS (diluted) | -1.08 | -0.93 | -0.79 | — | -0.65 | -0.40 | 1.90 | — |
| Weighted avg. shares (diluted) | 68.36M | 66.02M | 63.06M | — | 58.61M | 58.35M | 59.40M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $107.27M | $110.00M | $155.66M | $84.22M | $83.39M | $101.47M | $274.82M | $127.98M |
| Short-term investments | $211.92M | $182.81M | $187.89M | $200.45M | $164.92M | $146.24M | $82.51M | $88.92M |
| Receivables | $8.54M | $7.18M | $4.45M | $5.94M | $9.25M | — | — | $1.67M |
| Current assets | $354.42M | $322.54M | $366.68M | $305.70M | $272.44M | $269.97M | $375.74M | $232.76M |
| PP&E, net | $8.21M | $4.83M | $3.40M | $3.15M | $3.08M | $3.34M | $3.61M | $3.91M |
| Total assets | $406.69M | $393.97M | $443.28M | $418.43M | $360.26M | $384.51M | $406.89M | $271.56M |
| Current liabilities | $48.98M | $41.93M | $40.81M | $57.88M | $41.73M | $38.68M | $44.69M | $40.06M |
| Total liabilities | $54.10M | $48.42M | $48.40M | $65.98M | $52.16M | $49.56M | $56.81M | $42.53M |
| Shareholders' equity | $352.59M | $345.55M | $394.88M | $352.46M | $308.11M | $334.94M | $350.07M | $229.02M |
| Shares outstanding | 64.81M | 62.40M | 62.24M | 58.92M | 55.12M | 54.72M | 54.60M | 54.03M |
| Cash flow statement | ||||||||
| Operating cash flow | -$62.69M | -$56.59M | -$60.58M | -$30.45M | -$30.37M | -$25.42M | $131.83M | -$23.19M |
| Capital expenditure | $2.85M | $1.98M | $353,000 | $232,000 | $132,000 | $154,000 | $152,000 | $42,000 |
| Free cash flow | -$65.54M | -$58.56M | -$60.94M | -$30.69M | -$30.50M | -$25.58M | $131.68M | -$23.23M |
| Investing cash flow | -$10.21M | $9.02M | $50.69M | -$61.06M | $9.09M | -$148.48M | $13.63M | $819,000 |
| Financing cash flow | $70.16M | $1.91M | $84.33M | $92.34M | $3.12M | $554,000 | $1.37M | $568,000 |
| Depreciation & amortization | $455,000 | $458,000 | $439,000 | $405,000 | $442,000 | $446,000 | $477,000 | $526,000 |
| Stock-based compensation | $11.03M | $10.80M | $8.75M | $9.85M | $8.04M | $7.60M | $6.75M | $7.14M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.